Pharmaceutical

CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC

EMA's CHMP has recommended AstraZeneca's Tagrisso for approval in the European Union to treat individuals with NSCLC.

Nov 19, 2024 - 06:00
CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC
EMA's CHMP has recommended AstraZeneca's Tagrisso for approval in the European Union to treat individuals with NSCLC.
Read the original article

Tags:

Previous Article

AHA 2024: Tirzepatide improves outcomes for major heart failure with HFpEF and o...

Next Article

AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: White House official dings Bristol Myers Squibb for fighting off generic competition

STAT+: White House official dings Bristol Myers Squibb ...

Nov 29, 2023

Watch: P-value, an important measurement in clinical trials, explained

Watch: P-value, an important measurement in clinical tr...

Mar 20, 2023

AUR-101 by Aurigene Oncology for Psoriatic Arthritis: Likelihood of Approval

AUR-101 by Aurigene Oncology for Psoriatic Arthritis: L...

Jan 9, 2024